Aquinox to Present at the 17th Annual Needham Healthcare Conference

VANCOUVER, British Columbia, March 21, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 17th Annual Needham Healthcare Conference in New York on Wednesday, March 28^th 2018.

Aquinox Presentation Details

Date: Wednesday, March 28^th 2018
Time: 2:00 pm Eastern Time / 11:00 am Pacific Time                                  
Location: New York, NY – Westin New York Grand Central

A live audio webcast and archive of the event will be available at:

http://wsw.com/webcast/needham86/aqxp/

To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.

About Aquinox Pharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.

Investor Contact Info:

Brendan Payne
Associate Director, Investor Relations 
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]

Gitanjali Ogawa
Vice President 
The Trout Group

646-378-2949

[email protected]

You May Also Be Interested In

• Bridging Clinical Research and Patient Care: An Executive Q&A With Zebra MedNex CEO Brandy G. Robinson
• 4 Days, 18K+ Whitelisted, $0.0001 Stage 1: Why Apeing Is Suddenly Everywhere as the Upcoming Best Meme Coin Presale
• Too Hot for Hell ~ Kansas City's Legendary Haunted Attractions Concentrate 52nd Season Into 13 Nights